Table 9.
Adjuvant chemotherapy and adjuvant trastuzumab by tumour and patient characteristics in HER2-positive pT1a and pT1b breast cancers (n = 49)
| All HER2-positive tumours | HER2-positive tumours treated with adjuvant chemotherapy* | HER2-positive tumours treated with adjuvant chemotherapy and trastuzumab * | |
|---|---|---|---|
| No. of patients |
49 |
36 (73.5%) |
30 (61.2%) |
|
Menopausal status |
|
|
|
| pre- |
19 |
18 (94.7%) |
14 (73.7%) |
| post- |
30 |
18 (60.0%) |
16 (53.3%) |
|
Age (years) |
|
|
|
| 18–34 |
2 |
2 (100.0%) |
2 (100.0%) |
| 35–49 |
17 |
17 (100.0%) |
12 (70.6%) |
| 50–69 |
25 |
16 (64.0%) |
15 (60.0%) |
| ≥ 70 |
5 |
1 (20.0%) |
1 (20.0%) |
|
Hormonal receptor status |
|
|
|
| positive |
29 |
18 (62.1%) |
15 (51.7%) |
| negative |
20 |
18 (90.0%) |
15 (75.0%) |
|
LN status |
|
|
|
| pN0 |
43 |
30 (69.7%) |
24 (55.8%) |
| pN1 |
4 |
4 (100.0%) |
4 (100.0%) |
| pN2 |
2 |
2 (100.0%) |
2 (100.0%) |
|
Grading |
|
|
|
| G1 |
2 |
1 (50.0%) |
0 (0.0%) |
| G2 |
23 |
16 (69.6%) |
13 (56.5%) |
| G3 | 19 | 16 (84.2%) | 16 (84.2%) |
* Values and percentages are based on the all HER2-positive patients